Please select the option that best describes you:
What treatment options would you provide a HER2+/HR+ patient with significant residual disease s/p TCHP if they go on to develop severe neuropathy following adjuvant T-DM1 therapy?
Patient had an initial tumor response to TCHP, but still had significant residual disease present, including positive lymph nodes and residual breast tumor.
Answer from: Medical Oncologist at Community Practice
We know from the KATHERINE study that invasive disease or death had occurred in 12.6% of the T-DM1 group and in 22.2% of the trastuzumab group. The estimated percentage of patients who were free of invasive disease at 3 years was 88.3% in the T-DM1 group and 77.0% in the trastuzumab group. However, ...
Sign in or Register to read more